• P J Maguire, C Stevens, H D Humes, A Shander, N A Halpern, and S M Pastores.
• Department of Medical Affairs and New Technology Development, Vitagen Inc., La Jolla, California, USA.
• Crit Care Clin. 2000 Oct 1; 16 (4): 681-94.

AbstractThe current strategy to the treatment of SIRS and MODS uses a multidisciplinary approach that emphasizes supportive therapy. Herein, we have presented a futuristic approach that focuses on replacing the function of failed organs using bioartificial technology (Table 1). Bioartificial organ technology may allow the intensivist to provide physiologic organ replacement either as a bridge to transplantation or as a "time-buying" element until native organs that have become acutely dysfunctional or nonfunctional in a variety of clinical settings, can recover their function or regenerate their mass. As bioartificial organ technology matures, it is conceivable as an ultimate goal that non-immunogenic bioartificial organs would be miniaturized or redesigned and acutely placed within the intracorporeal space as replacement organs.

14 keywords...

hide…